rituximab
The Case for Switching to Rituximab Biosimilar
Switching from originator rituximab to rituximab-abbs can save an institution up to $13,000 annually per patient ...
FEBRUARY 16, 2022
Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% ...
DECEMBER 28, 2021
FDA Approves Rituxan Plus Chemotherapy for Pediatric Hematologic Cancers
The FDA approved rituximab (Rituxan, Genentech) in combination with chemotherapy for pediatric patients (≥6 ...
DECEMBER 8, 2021
Rituximab Plus Standard Chemo Increases Survival for Pediatric B-Cell NHL
Adding rituximab to a lymphomes malins B (LMB) chemotherapy regimen increased three-year survival from 87% to 95% ...
JULY 27, 2020
Revlimid-Rituximab Combo Approved for FL and MZL
The FDA approved lenalidomide (Revlimid, Celgene) in combination with a rituximab product for previously treated ...
JUNE 4, 2019
Some Chemoimmunotherapy Regimens May Reactivate HBV in B-Cell NHL
Data from two phase 3 studies of patients with B-cell non-Hodgkin lymphoma (NHL) with resolved hepatitis B virus ...
FEBRUARY 11, 2019
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
SABRINA Trial Indicates Subcutaneous Rituximab Equivalent to IV Form
A formulation of rituximab administered by subcutaneous injection appears to be just as safe and effective in the ...
JUNE 1, 2017
Rituximab After Auto-HCT Prolongs Survival in MCL
San Diego—In younger patients with mantle cell lymphoma (MCL) who have received an autologous hematopoietic ...
APRIL 15, 2017
ASH Report: Obinutuzumab Beats Rituximab in Follicular Lymphoma
San Diego—For front-line therapy of follicular lymphoma (FL), an obinutuzumab-based induction and maintenance ...
JANUARY 30, 2017
Chemotherapy-Free Induction Possible With Ibrutinib-Rituximab
Patients with mantle cell lymphoma may be able to undergo induction treatment with a combination of ibrutinib and ...
JANUARY 5, 2017